Opinion|Videos|June 12, 2024
Optimizing Benefit Design and Implementation for Improved PDT Access
Panelists explore how payers choose between pharmacy and medical benefit designs for covering prescription digital therapeutics (PDTs), optimizing patient access and adoption, and discussing why the selected pathway was considered optimal for a specific PDT.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- How do payers determine the optimal pharmacy vs. medical benefit design to cover prescription digital therapeutics (PDTs) to enhance patient access and adoption?
- What factors and considerations went into the decision to cover a particular PDT through the pharmacy benefit versus the medical benefit, and why was that pathway determined to be optimal for that specific PDT?
- What characteristics and factors did Mass Health consider when selecting clinics to prescribe and implement the use of prescription digital therapeutics?
Advertisement
Related to this article
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply
At inSPire2026, experts highlighted gaps in specialty therapy payment, 340B data, clinical trials, and AI-driven care.
The approval is based on findings from the phase 3 SCOUT-HCM trial.
Advertisement
Advertisement
Trending on AJMC
1
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
2
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
3
FDA Expands Mavacamten Label to Include Children With oHCM
4
FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers
5